Literature DB >> 8282523

Hyperammoniemic coma in an adolescent girl: an unusual case of ornithine transcarbamylase deficiency.

M Perini1, D Zarcone, C Corbetta.   

Abstract

Ornithine transcarbamylase deficiency (OTCD) is caused by an alteration of urea synthesis, linked with partial modification of the X-chromosome, whose clinical manifestations are: lethargy, nausea, vomiting and cerebral edema. While in newborn males OTCD presents with hyperammoniemia leading to cerebral palsy with profound neurological impairment and eventually death, in women who are healthy carriers, it is possible to detect the disorder only through specific tests, since heterozygote women are rarely symptomatic. We describe the case of a young woman admitted to the hospital after an episode of mental confusion with vomiting and psychomotor restlessness, which had previously occurred several times during the premenstruum and lasted a few hours. A 2 day history of stupor made admission mandatory. Tests carried out during the hospital stay showed marked hyperammoniemia and unconjugated hyperbilirubinemia, marked cerebral edema documented by a CT scan. Liver biopsy and CSF test were normal. Screening of plasma and urinary aminoacids, level of orotic acid in the urine and OTC activity in the liver, confirmed the diagnosis of OTCD. The possibility of early diagnosis and therapy of a disease which otherwise leads to death, emphasizes the importance of precise evaluation of a possible organic cause of anorexia and behaviour disorders in young women.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8282523     DOI: 10.1007/BF02339177

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  11 in total

1.  Acute hemiparesis as the presenting sign in a heterozygote for ornithine transcarbamylase deficiency.

Authors:  T J de Grauw; L M Smit; M Brockstedt; Y Meijer; J vd Klei-von Moorsel; C Jakobs
Journal:  Neuropediatrics       Date:  1990-08       Impact factor: 1.947

2.  Allopurinol-induced orotidinuria. A test for mutations at the ornithine carbamoyltransferase locus in women.

Authors:  E R Hauser; J E Finkelstein; D Valle; S W Brusilow
Journal:  N Engl J Med       Date:  1990-06-07       Impact factor: 91.245

3.  Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. A cause of postpartum coma.

Authors:  P H Arn; E R Hauser; G H Thomas; G Herman; D Hess; S W Brusilow
Journal:  N Engl J Med       Date:  1990-06-07       Impact factor: 91.245

4.  Ornithine transcarbamylase deficiency in a boy with long survival.

Authors:  C Largilliere; J P Farriaux
Journal:  J Pediatr       Date:  1988-11       Impact factor: 4.406

5.  Reye's syndrome: relation of outcome to therapy.

Authors:  P R Huttenlocher
Journal:  J Pediatr       Date:  1972-05       Impact factor: 4.406

6.  Late-onset ornithine transcarbamylase deficiency in male patients.

Authors:  J E Finkelstein; E R Hauser; C O Leonard; S W Brusilow
Journal:  J Pediatr       Date:  1990-12       Impact factor: 4.406

7.  Improved molecular diagnostics for ornithine transcarbamylase deficiency.

Authors:  M Grompe; C T Caskey; R G Fenwick
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

8.  An arginine to glutamine mutation in residue 109 of human ornithine transcarbamylase completely abolishes enzymatic activity in Cos1 cells.

Authors:  J T Lee; R L Nussbaum
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

9.  Natural history of symptomatic partial ornithine transcarbamylase deficiency.

Authors:  P C Rowe; S L Newman; S W Brusilow
Journal:  N Engl J Med       Date:  1986-02-27       Impact factor: 91.245

10.  Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency.

Authors:  M L Batshaw; M Msall; A L Beaudet; J Trojak
Journal:  J Pediatr       Date:  1986-02       Impact factor: 4.406

View more
  1 in total

Review 1.  Brain imaging in urea cycle disorders.

Authors:  Andrea Gropman
Journal:  Mol Genet Metab       Date:  2010-02-13       Impact factor: 4.797

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.